Eli Lilly & Co. vs Abbvie Inc.
LLY vs ABBV — side-by-side comparison from reported financials. LLY leads 9, ABBV leads 3 of 12 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | LLY | ABBV |
|---|---|---|
| Price | $1 177.20 | $276.43 |
| Market cap | $1.05T | $488B |
| Revenue (TTM) | $79.7B | $64.4B |
| Revenue growth | +31.7% | +1.8% |
| Net margin | 33.5% | 9.8% |
| Free cash flow | $18.2B | $18.2B |
| Net cash (debt) | ($35.2B) | ($56.2B) |
| 1-year price return | +37.6% | +19.8% |
| P/E | 41.6 | 77.4 |
| P/E vs own history (cheap-side %) | 88% | 23% |
| Dividend yield | 0.52% | 2.45% |
| Return on equity | 93% | 96% |
| Altman Z-score | 7.10 | 2.33 |
| CV checks passed | 11 of 11 | 9 of 11 |
| Employees | 50,000 | 57,000 |
Full résumé-style profiles: LLY CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.